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INTRODUCTION
Respiratory tract infections (RTIs) are amongst the
most widespread and serious infections accounting for
over 50 million deaths globally each year.1 They are
also the most common reason for physician’s visit and
antibiotic prescription.2  The prevalence of  pneumonia
among adults with respiratory symptoms suggesting
pneumonitis ranges from only 3% in a general
outpatient setting to 28% in emergency department.
3,4 Community-acquired pneumonia (CAP) is a
common cause of hospital admission in Nigeria, and,
in TB patients attending a TB clinic in South-Western
Nigeria, 6.4% was found to have Streptococcal pneumoniae.5
Initial antibiotic therapy in upper and lower respiratory
tract infections is usually empirical, focused towards
the most common aetiologic agents, which include,
Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella
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pneumoniae and Moraxella catarrhalis.6 However,the
decreasing susceptibility patterns of these pathogens,
particularly S.pneumoniae  and H.influenzae , to
antibacterials have raised concerns about the decreasing
efficacy of  currently available antibiotics.7,8 In the United
States, almost 100% of  clinical M. catarrhalis and up to
50% of H.influenzae  isolates produce beta-lactamase.
Penicillin-resistant strains have been identified
worldwide,9 and, resistance to other antibacterials such
as cephalosporins, fluoroquinolones and macrolides
is increasing among isolates of S.pneumoniae.10-12
Cefixime belongs to the third -generation cephalosporin
antibiotics that exert their bactericidal effect by attaching
to penicillin-binding proteins and inhibiting
peptidoglycan synthesis, thus causing damage to the










Background: Initial antibiotic therapy in upper and lower respiratory tract
infections is usually empirical. However, the decreasing susceptibility of
respiratory pathogens to antibacterials have raised concerns about the decreasing
efficacy of currently available antibiotics.
Objective: This study was conducted to compare the efficacy and safety of cefixime
and ciprofloxacin in the empirical treatment of  community-acquired pneumonia
among adult Nigerian patients in Ibadan.
Methods:  This was an open-labelled, randomized, parallel-group study of seventy-
three (73) radiologically and bacteriologically confirmed adult cases of
community-acquired pneumonia, between July 1 and September 31, 2011 at two
health care facilities in Ibadan, Nigeria. All of these patients had severity index
(CURB 65) scores of either 1 or 2. They were treated with either Cefixime, 400mg
twice daily or Ciprofloxacin 500mg twice daily for 14 days. They were evaluated
four times during the course of their treatment for clinical responses, radiological
and bacteriological clearances and safety of  therapy.
Results:  There were 39 (53.4%) patients in the Cefixime group and 34(46.6%) in
Ciprofloxacin group. On day 7, patients on cefixime had a statistically significant
lower temperature than patients on ciprofloxacin (P<0.01). By day 14, only 10.3%
of patients in cefixime group still had persistent residual radiological changes
compared to 38.2% in the ciprofloxacin group (P < 0.01). Bacteria cure was obtained
in 96% of  the patients in the cefixime group and 83% in the ciprofloxacin group.
Conclusion: Cefixime was found to be superior to ciprofloxacin in terms of  efficacy
in the treatment of community-acquired pneumonia in adults in Nigeria. However,
both antibiotics were well-tolerated by all the patients as there were no reports or
documentation of adverse events.
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are used all over the world because of their broad
spectrum activity against all Gram-negative and positive
pathogens and atypical organisms, e.g. Mycoplasma
and Chlamydia.6
Ciprofloxacin, also a broad-spectrum, early-generation
fluoroquinolone, is one of the cheap and most
commonly used antibiotics for most infections
including RTI in this community, and, it exhibits
bactericidal activity primarily by inhibiting bacterial
DNA gyrase. These drugs were acceptable standard
antibiotics for the treatment of community-acquired
pneumonia during the study period. Even though there
are many antibiotics that require less frequent
administration, some studies indicate that older
antibiotics that have fallen out of favour, are still
effective for treatment of community-acquired
pneumonia.13 This study was therefore conducted to
evaluate the comparative efficacy and safety of
Cefixime and Ciprofloxacin in the empirical treatment
of CAP among adult Nigerian patients in Ibadan,
Nigeria.
PATIENTS AND METHODS
Study population, enrolment and therapy
This was an open-labelled, randomized, parallel-group
study conducted at the General Out Patient
Department of the University College Hospital (UCH),
Ibadan and Saint Mary’s Catholic Hospital, Eleta,
Ibadan, Nigeria, between July 1 and September 31,
2011.
The first 75 subjects who satisfied the inclusion criteria
were randomised into Cefixime and Ciprofloxacin
groups. However, 2 of  these were lost to follow-up
as they failed to turn up for subsequent visits to the
clinic, leaving 73 to conclude the study.
The major inclusion criteria included: adult above 18
years of age, recent onset of fever (>38.3oC), cough
with purulent expectoration, bacteriologically positive
sputum, presence of an infiltrate on chest radiography
performed within 72 hours after the first clinical
examination, pleuritic chest pain,  crackles, new onset
of dyspnea, or worsening dyspnea, female of child
bearing potential with a negative urine pregnancy test
prior to enrolment (including those who were practising
birth control, those with tube ligation and those less
than 1 year post-menopausal),willingness to partake in
the study and provision of  a signed informed or
witnessed verbal informed consent.
The key exclusion criteria included: patients with
bacteriologically negative sputum,  negative chest
radiograph, on antibiotics for any infective conditions
within the preceding 30 days, hypersensitivity to
quinolones or cephalosporins or a severe allergic
reaction to any other drug in the past, especially
penicillin, patients with other chronic pulmonary
diseases like  active tuberculosis, bronchiectasis, or active
pulmonary malignancies, patients with a life threatening
or serious underlying disease, which is unstable, e.g.
myocardial infarction, patients with known or
suspected renal impairment and/or known creatinine
clearance <40ml/min, patients with ALT, AST, or
alkaline phosphatase levels 3 times greater than the
upper limit of  normal, patients who were immuno-
compromised including HIV positive patients, patients
whose initial clinical status justified immediate
hospitalization, and these were provided with hospital
admission and excluded from the study.
A complete medical history was obtained and physical
examination conducted on all the patients prior to entry
into the study. Patients whose severity index (CURB
65) score were 1 or 2 were enrolled and those whose
scores were higher than these were excluded from the
study as many of these needed to be admitted.
Enrolment was made after obtaining bacteriologically
positive sputum and positive chest radiograph results
from any of the patients apart from other inclusion
criteria. Each eligible patient was assigned by a
computer-generated sequence of random numbers to
receive either Cefixime, 400mg twice daily or
Ciprofloxacin, 500mg twice daily for 14 days.
Enrolled patients were followed up during treatment
at the Medical Out-Patient Department of the
respective study hospitals. Each study participant
received the first dose of any of the 2 antibiotics on
the first day of the study which corresponded to the
time after positive radiological and bacteriological
reports were obtained.
This was supervised by  the study nurse  and patients
were then  encouraged to take subsequent doses of
the respective antimicrobial agent daily till the next
follow up clinic visit. Compliance with drug regimen
was crosschecked by direct questioning and pill count
at every follow up clinic visit.  Study participants were
followed up on days 1, 3, 7, and 14.
Prior to enrolment, sputum samples were collected in
sterile sputum cups and were transferred to the
laboratory in a cold box the same day for laboratory
evaluation. Pathogens were isolated and identified from
sputa using standard bacteriological methods. Identified
pathogens were then subjected to antibiotics
susceptibility test to cefixime and ciprofloxacin using
the Kirby-Bauer disc diffusion method.14 Sputum
collection was repeated on days 3, 7 and 14 to check
for bacteriological clearance.
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Ten milliliters of  blood was obtained by venepuncture
for full blood count and blood chemistry evaluation
which included aspartate aminotransaminase (AST),
alanine aminotransaminase (ALT), total bilirubin,
electrolyte & urea and serum creatinine.
The laboratory investigations were conducted at the
diagnostic medical microbiology, hematology and
chemical pathology laboratories of  University College
Hospital Ibadan. Full blood count and differentials as
well as biochemical parameters were again re-evaluated
on day 14. Chest X-rays (posterior anterior & lateral
views) were taken at the UCH or Saint Mary’s Catholic
Hospital, Eleta X-ray Departments prior to
commencement of treatment and on day 14.
Efficacy and safety parameters
Patients were evaluated four times during the course
of treatment. The primary efficacy was to evaluate
the comparative clinical response at the two arms of
treatment on days 3, 7 and 14. Secondary efficacy
parameters included the comparative radiological
response at the end of therapy and bacterial eradication
rate on days 3,7 and 14. The bacterial sensitivity to
Cefixime and Ciprofloxacin was determined for each
isolated bacteria, irrespective of the treatment group
assigned. The organisms were considered sensitive to
Cefixime when the inhibition halo was equal to or
greater than 19 mm and sensitive to Ciprofloxacin
when the halo was equal or greater than 21 mm.15
 The bacteriologic response was considered satisfactory
if the causative organism had been eradicated with
treatment. Radiologic response was considered
satisfactory when the lobar consolidation noticed at
the beginning of treatment has cleared completely on
day 14 of antibiotics therapy as reported by the
consultant radiologist.
The safety end point was to evaluate the incidence of
adverse effects and laboratory parameters.
Statistical analysis
Data generated was entered using epidata program
and the SPSS version 16 was used for further statistical
analysis. Frequency tables, graphs and summary index
were used for data presentation. The student t-test was
used to investigate the statistical significance of the
quantitative effects of the two drugs between the two
groups.
Ethical considerations
All patients enrolled gave written informed consent
and the trial was approved by the Joint Ethical
Committee of the University College Hospital/
University of Ibadan, Nigeria.
RESULTS
Seventy-five patients that satisfied the inclusion criteria
were recruited for this open-labelled, randomised,drug
trial but two were lost to follow-up as they failed to
turn up for subsequent visits to the clinics as scheduled.
One was from each arm of  the treatment leaving 39
in the cefixime group and 34 in the ciprofloxacin group.
Table 1 shows the anthropometric characteristics of
the patients from the two arms of  treatment.
Primary efficacy parameter is the clinical response on
follow up in each treatment group. Table 2 shows the
clinical features of patients allocated to the 2 treatment
groups while Table 3 shows the summary of  statistics
of patients’ clinical characteristics on each day of
follow-up in each treatment group.
The temperature pattern shows that the temperatures
decreased slightly in both groups by day 3 but not
statistically significant (P>0.2). However, on day 7,
patients on cefixime had a statistically significant lower
temperature than patients on ciprofloxacin (P<0.01).
The same was observed with regards to the respiratory
rate. This pattern was maintained on day 14 during



































Table 1: Anthropometric characteristics of  patients in the 2 arms of  treatment.








































































Table 3: Summary of  statistics of  patients’ clinical characteristics on each day of  follow-up in each treatment
group.
* Statistically significant differences between the two treatment groups.
TEMP= Temperature
PR=   Pulse rate
RR= Respiratory rate



















































































Table 2: Summary Statistics of  the duration of  Symptoms in days of  patients allocated to cefixime and
ciprofloxacin treatment groups.


































*Statistically significant differences between the 2 treatment groups.
Table 4: Percentage bacteria eradication rate and radiological clearance at follow-up of  patients in Cefixime
and Ciprofloxacin groups.
Patients with radiological consolidations and bacterial isolates
                                                   Annals of Ibadan Postgraduate Medicine. Vol. 13 No. 2, December 2015              75
Table 4 shows the results of  the secondary efficacy
parameters of  the two drugs in terms of  their bacterial
eradication rates and radiological clearance at follow-
up of  the patients. The distribution of  lung lesions
and percentage clearance on days 1 and 14 in the 2
treatment groups is demonstrated in Table 5. The
predominant bacterial aetiology of  community-
acquired pneumonia in this study was Staphylococcus
aureus 29 (39.7%), followed by Streptococcus pneumoniae
11(15.1%), Klebsiella pneumoniae 10(13.7%), Escherichia coli
17(23.3%) and Proteus mirabilis 6 (8.2%).
As regards the safety parameters considered for the
two drugs, there were no adverse drug effects
observed or reported by any of  the patients in the
two arms of  treatment. The liver function tests, urea
and creatinine, complete blood counts were essentially
of  normal values in all the patients at baseline and end
of treatment.
DISCUSSION
Community-acquired pneumonia (CAP) is a cause of
substantial morbidity, mortality, and resource utilization
worldwide. Despite substantial progress in therapeutic
options, CAP remains a significant cause of morbidity
and death, and, there continues to be a major
controversy concerning the antimicrobial management
of  this infection.16 The mixed aetiology and the
changing susceptibility of  pathogens causing CAP, in
particular, that of Streptococcus pneumoniae, has created a
challenge, in some circumstances, to clinicians in terms
of optimal outcome.17
Initial antimicrobial therapy is normally given
empirically before the bacterial cause of the infection
can be determined in the laboratory, and, in many cases,
treatment is empirical throughout due to lack of
reliable microbiological data. An understanding of the
possible pathogens and resistant patterns is therefore
helpful in guiding antibiotic choice. A detailed
knowledge of the local susceptibility of the potential
pathogens would ensure a more appropriate selection
of the antimicrobial agent to be used.18,19 In this
environment, ciprofloxacin is the most commonly used
antibiotics for management of infections including
RTIs, being the most readily available and very cheap,
which leads to the comparison of  it’s efficacy and
safety with cefixime  in this study.
The choice of these empirical antibiotics for CAP in
this study was in conformity with the guildelines of
IDSA (Infectious Disease Society of America)/ATS
(American thoracic society)/Canadian guidelines
(CIDS,CTS).20-23 The major criterion that guided the
management decision of the CAP patients revolved
around the initial assessment of the severity since the
oral route can only be recommended in these non-
severe (mild to moderate) pneumonia which was the
case in this study.22,23
The finding of persistent residual radiological changes
in this study is in keeping with the observation of  earlier
researchers that radiographic response to treatment
usually lags behind clinical improvement and
pneumococcal pneumonia may take 6 weeks to clear
on the chest film.24,25 This delay of the radiographic
clearing that contrasts with the rapid clinical response
seen on the third day of antibiotic treatment was  one





























































Table 5: Distribution of  the lung lesions and percentage clearance on days 1 and 14 in Cefixime and Ciprofloxacin
drug groups.
Left lower and right lower zones were the zones mostly affected by the consolidative changes on chest-x-ray accounting for 92.1%.
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The results of our study show that cefixime
administered at the dose of 400mg twice daily is an
effective oral antibiotic treatment in the management
of  community-acquired pneumonia in adults. This is
in keeping with most previous clinical studies that
found it very effective for lower respiratory tract
infections.26-32 The efficacy of  cefixime in acute
exacerbation of chronic bronchitis (AECB) has also
been well documented in both comparative and non-
comparative clinical studies.33,34.
In this study, the predominant cause of  community-
acquired pneumonia was Staphylococcus aureus 29 (39.7%),
followed by Streptococcus pneumoniae 11(15.1%), Klebsiella
pneumoniae 10(13.7%), Escherichia coli 17(23.3%) and
Proteus mirabilis 6 (8.2%).
This is contrary to a study conducted in the United
States in 2006, where, in approximately 4.2 million
ambulatory care visits for CAP, Streptococcus pneumoniae
was the most commonly identified pathogen.35-37
None of the patients experienced vital signs of
potential clinical concern or reported any adverse events
during the course of  study in the two arms of
treatment. Cefixime was found to be safe and well
tolerated in all the patients which contrasts the previous
documentation of mild or moderate diarrhea and
epigastric discomfort.31-33 Thus, cefixime was shown
to be superior to ciprofloxacin in the treatment of
bacterial pneumonia among adults who have been
properly assessed not to need hospitalization in Nigeria.
Limitation of the study
The clinical efficacy of Cefixime should also be
compared with the new-generation fluoroquinolones
(clionfloxacin, gemifloxacin, levofloxacin or
moxifloxacin) and with another potent third-
generation cephalosporins (cefpodoximeproxetil).
The on-going research will address this and help the
clinicians with the right choice of empiric antibiotic
treatment of CAP in Nigeria.
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